ANI Pharmaceuticals Inc (ANIP)
63.68
+0.59
(+0.94%)
USD |
NASDAQ |
Jun 28, 16:00
63.58
-0.10
(-0.16%)
After-Hours: 20:00
ANI Pharmaceuticals SG&A Expense (Annual): 161.70M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 161.70M |
| December 31, 2022 | 124.04M |
| December 31, 2021 | 84.29M |
| December 31, 2020 | 64.99M |
| December 31, 2019 | 55.84M |
| December 31, 2018 | 44.06M |
| December 31, 2017 | 31.58M |
| December 31, 2016 | 27.83M |
| December 31, 2015 | 21.16M |
| December 31, 2014 | 17.94M |
| December 31, 2013 | 16.39M |
| December 31, 2012 | 8.230M |
| December 31, 2011 | 6.982M |
| Date | Value |
|---|---|
| December 31, 2010 | 5.940M |
| December 31, 2009 | 5.374M |
| December 31, 2008 | 5.961M |
| December 31, 2007 | 4.331M |
| December 31, 2006 | 7.025M |
| December 31, 2005 | 3.051M |
| December 31, 2004 | 3.080M |
| December 31, 2003 | 2.327M |
| December 31, 2002 | 1.766M |
| December 31, 2001 | 2.299M |
| December 31, 2000 | 1.679M |
| December 31, 1999 | 0.8534M |
| December 31, 1998 | 1.113M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
55.84M
Minimum
2019
161.70M
Maximum
2023
98.17M
Average
84.29M
Median
2021
SG&A Expense (Annual) Benchmarks
| Ligand Pharmaceuticals Inc | 52.79M |
| ADMA Biologics Inc | 59.02M |
| Annovis Bio Inc | 6.244M |
| Alimera Sciences Inc | 46.48M |
| United Therapeutics Corp | 477.10M |